---
title: "Biotech financings Oct 26 to Nov 1: Repligen, Rapport lead"
url: "https://aibio.space/analysis/biotech-financing-roundup-week-2026-11-01/"
publisher: "aibio.space"
date: "2026-11-01"
tickers: "NASDAQ:RGEN"
summary: "Eight biotech companies sold stock or convertible notes in the week to November 1st."
---

By aibio.space

[REPLIGEN CORP company page](https://aibio.space/companies/repligen/)

2026-11-01

# Big borrowers, deep discounts: the week in biotech financing

Eight biotech companies sold stock or convertible notes in the week to November 1st. The largest deal was debt, and most of the share sales priced well below the market.

[RGEN](https://aibio.space/companies/repligen/) [RAPP](https://aibio.space/companies/rapport-therapeutics/) [ACRS](https://aibio.space/companies/aclaris-therapeutics/) [EQ](https://aibio.space/companies/equillium/) [ACTU](https://aibio.space/companies/actuate-therapeutics/) [INMB](https://aibio.space/companies/inmune-bio/) [ALT](https://aibio.space/companies/altimmune/) [VBIO](https://aibio.space/companies/valion-bio/)

Two deals took most of the money raised by listed life-science companies in the week to November 1st. Repligen arranged $1bn of convertible notes and Rapport Therapeutics raised about $380m in stock, notes and a private placement. Two clinical-stage companies, Bambusa Therapeutics and Aspen Neuroscience, went public. Smaller sales, most priced under the last trade, followed. Figures come from SEC filings and releases, linked below; where a filing omits a number, we say so.

## The ranking

**1. Repligen ([RGEN](https://aibio.space/companies/repligen/)), $1.0bn convertible notes.** The maker of bioprocessing equipment [agreed on October 29th](https://www.sec.gov/Archives/edgar/data/730272/000162828026068382/rgen-20261029.htm) to issue 0.25% notes due 2031 in privately negotiated deals. About $541.4m will be swapped for roughly $456.8m of its 1.00% notes due 2028, and about $458.6m sold for cash. The conversion price of about $226.37 is a 20.0% premium to the $188.64 last sale. Around $120.0m of the cash goes on buying back Repligen shares from some note buyers. The [release](https://www.sec.gov/Archives/edgar/data/730272/000162828026068382/rgen-20261030xexx992.htm) names J. Wood Capital Advisors as placement agent. Olivier Loeillot, chief executive, and Jason K. Garland, chief financial officer, signed the [third-quarter 10-Q](https://www.sec.gov/Archives/edgar/data/730272/000162828026068562/rgen-20260930.htm) on October 30th. Our [analysis](https://aibio.space/analysis/repligen-rgen-1b-convertible-notes-terms/) covers the terms in full.

**2. Rapport Therapeutics ([RAPP](https://aibio.space/companies/rapport-therapeutics/)), about $380m in four parts.** On October 28th the neurology drug developer [priced](https://www.sec.gov/Archives/edgar/data/2012593/000119312526435030/d54357dfwp.htm) about $175.0m of stock at $21.00, $25.0m of pre-funded warrants, $150.0m of 2.25% convertible notes due 2032 and a $30.0m private placement at the offering price with an unnamed investor. The stock price is 23.7% below the $27.54 close on October 27th given in the [pricing term sheet](https://www.sec.gov/Archives/edgar/data/2012593/000119312526435057/d59324dfwp.htm), a close that was up from $25.33 the day before, according to the [preliminary prospectus](https://www.sec.gov/Archives/edgar/data/2012593/000119312526434371/d348288d424b5.htm). The notes convert at about $26.78, a 27.5% premium to the offering price. Morgan Stanley & Co. LLC, Leerink Partners LLC and Evercore Group L.L.C. ran both underwritten deals, with BTIG, LLC and Citizens JMP Securities, LLC joining on the stock. The [8-K](https://www.sec.gov/Archives/edgar/data/2012593/000119312526441851/d49801d8k.htm) says the money goes mainly to trials of RAP-219, and the term sheet says cash should last through the end of 2029. Abraham N. Ceesay is chief executive and Troy Ignelzi chief financial officer; both signed the [latest 10-Q](https://www.sec.gov/Archives/edgar/data/2012593/000119312526333862/rapp-20260630.htm), and Ignelzi signed the 8-K.

**3. Bambusa Therapeutics (BBTX), $168.9m IPO.** Bambusa [sold](https://www.sec.gov/Archives/edgar/data/2044950/000162828026068563/0001628280-26-068563.txt) 10,555,555 shares at $16.00 for a Nasdaq listing, under a prospectus dated October 29th. It has not yet reported the closing or any exercise of the underwriters' option for 1,583,333 more shares. BofA Securities, Inc., Evercore Group L.L.C., UBS Securities LLC and Cantor Fitzgerald & Co. underwrote it. About $90.0m is earmarked for a Phase 2b study of its lead antibody, BBT001, and about $40.0m for its second candidate. The prospectus says the money stretches cash into late 2028. Without it, the company reported about $57.2m on September 30th and substantial doubt about its ability to continue as a going concern. Shanshan Xu is co-founder and chief executive. Jonathan I. Lieber is chief financial officer and, the prospectus says, also serves part-time as CFO of Rallybio.

**4. Aspen Neuroscience (ASPE), $140.6m IPO.** Aspen [sold](https://www.sec.gov/Archives/edgar/data/2124080/000119312526441782/0001193125-26-441782.txt) 9,375,000 shares at $15.00 under a prospectus dated October 29th. The underwriters are Leerink Partners LLC, Piper Sandler & Co., Stifel, Nicolaus & Company, Incorporated, UBS Securities LLC and Oppenheimer & Co. Inc. Delivery was set for November 2nd, so the closing and any use of the option for 1,406,250 more shares are not yet reported. The money funds its Parkinson's cell therapy, sasineprocel, through the ASPIRO trial and into a planned Phase 3, and the prospectus says it lasts into the second half of 2028. Before the deal the company also disclosed a going-concern doubt. Damien McDevitt is president and chief executive and Dalen Meeter chief financial officer, per the prospectus.

**5. Aclaris Therapeutics ([ACRS](https://aibio.space/companies/aclaris-therapeutics/)), $50.0m stock and pre-funded warrants.** Aclaris [sold](https://www.sec.gov/Archives/edgar/data/1557746/000110465926119223/tm2627632-2_424b5.htm) 7,785,714 shares at $3.50 and pre-funded warrants on 6.5m more, 7.7% below the $3.79 close. The underwriters are Leerink Partners LLC, Piper Sandler & Co., Cantor Fitzgerald & Co. and LifeSci Capital LLC. Proceeds go to its pipeline and general purposes; no runway date is given. Neal Walker is chief executive and Kevin Balthaser chief financial officer, per the [latest 10-Q](https://www.sec.gov/Archives/edgar/data/1557746/000110465926092065/acrs-20260630x10q.htm). [Our coverage](https://aibio.space/news/aclaris-therapeutics-prices-49-999-934-stock-pre-funded-warrant/).

**6. Equillium ([EQ](https://aibio.space/companies/equillium/)), $20.0m private placement tranche.** The first dose of EQ504 in a healthy-volunteer trial [triggered](https://www.sec.gov/Archives/edgar/data/1746466/000119312526432158/d67574dex991.htm) a milestone closing under its August 2025 placement: 14,957,260 shares at $0.57 and 20,130,457 pre-funded warrants at $0.5669. Yahoo Finance data put the October 23rd close at $1.23, so the tranche price is about 54% below the market. The release ties the closing to the August 2025 placement and does not say whether the price was reset. The release mentions a "Price Threshold Waiver" without explaining it, and names no investors or agent. The company says cash now lasts into 2029. Bruce D. Steel signed the [latest 10-Q](https://www.sec.gov/Archives/edgar/data/1746466/000119312526349235/eq-20260630.htm) as chief executive and principal financial officer; the company lists no separate CFO. [Our coverage](https://aibio.space/news/first-eq504-dosing-unlocks-20-million-private-placement-tranche/).

**7. Actuate Therapeutics ([ACTU](https://aibio.space/companies/actuate-therapeutics/)), $11.0m stock and warrants.** Actuate [sold](https://www.sec.gov/Archives/edgar/data/1652935/000168316826008122/actuate_424b5.htm) units of two shares and one five-year warrant at $0.71, an effective $0.355 a share against a $0.40 close, an 11% discount. Each warrant exercises at $0.45. Newbridge Securities Corporation was sole bookrunner. Proceeds are for working capital, with no runway given. Daniel Schmitt is president and chief executive and Paul Lytle chief financial officer, per the [latest 10-Q](https://www.sec.gov/Archives/edgar/data/1652935/000168316826006472/actuate_i10q-063026.htm). [Our coverage](https://aibio.space/news/actuate-therapeutics-prices-11-0-million-offering-shares-warrants/).

**8. INmune Bio ([INMB](https://aibio.space/companies/inmune-bio/)), $4.5m registered direct.** One institutional investor [bought](https://www.sec.gov/Archives/edgar/data/1711754/000121390026113531/ea0308597-424b5_inmune.htm) 3m shares at $1.50, 1.3% below the $1.52 close, plus warrants on 3m more at $1.65. A.G.P./Alliance Global Partners was placement agent. The money supports CORDStrom and working capital. David Moss is chief executive and Cory Ellspermann chief financial officer, per the [latest 10-Q](https://www.sec.gov/Archives/edgar/data/1711754/000121390026086135/ea0298894-10q_inmune.htm). [Our coverage](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/).

**Debt and other.** Altimmune ([ALT](https://aibio.space/companies/altimmune/)) [drew $10.0m](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000060/alt-20261027x8k.htm) from its $125.0m Hercules Capital facility, extending interest-only payments to June 2028 and switching on a covenant to hold cash of at least 60% of the loan balance. Valion Bio ([VBIO](https://aibio.space/companies/valion-bio/)) sold $4.7m of preferred stock but [receives](https://www.sec.gov/Archives/edgar/data/1787740/000143774926033552/vbio20261023_8k.htm) only $1.5m in cash; the buyers keep the rest to settle overdue true-up payments. Vor Biopharma filed a $150m [at-the-market prospectus](https://www.sec.gov/Archives/edgar/data/1817229/000119312526439975/0001193125-26-439975.txt) with William Blair and RBC, and ProKidney, Lexeo and Acumen filed shelves; none of these has raised money yet.

## The deals at a glance

| Rank | Company | Date | Type | Size | Price | vs prior close | Warrants | Leads / agents | Runway stated |
|---|---|---|---|---|---|---|---|---|---|
| 1 | Repligen (RGEN) | Oct 29 | Private convertible notes, 0.25%, 2031 | $1.0bn ($458.6m cash) | Conv. $226.37 | +20.0% premium | None | J. Wood Capital Advisors | Not stated |
| 2 | Rapport (RAPP) | Oct 28 | Stock, pre-funded warrants, 2.25% converts, private placement | ~$380m | $21.00; conv. $26.78 | -23.7% (stock, vs Oct 27) | Pre-funded | Morgan Stanley, Leerink, Evercore | End of 2029 |
| 3 | Bambusa (BBTX) | Oct 29 | IPO | $168.9m | $16.00 | n/a | None | BofA Securities, Evercore, UBS Securities, Cantor Fitzgerald | Into late 2028 |
| 4 | Aspen (ASPE) | Oct 29 | IPO | $140.6m | $15.00 | n/a | None | Leerink Partners, Piper Sandler, Stifel, UBS Securities, Oppenheimer | Into 2H 2028 |
| 5 | Aclaris (ACRS) | Oct 27 | Follow-on | $50.0m | $3.50 | -7.7% | Pre-funded | Leerink Partners, Piper Sandler, Cantor Fitzgerald, LifeSci Capital | Not stated |
| 6 | Equillium (EQ) | Oct 26 | Private placement milestone tranche | $20.0m | $0.57 | About -54% (Yahoo Finance, Oct 23) | Pre-funded | Not named | Into 2029 |
| 7 | Actuate (ACTU) | Oct 27 | Units, stock and warrants | $11.0m | $0.355 effective | -11.3% | 5-yr, $0.45 | Newbridge Securities | Not stated |
| 8 | INmune Bio (INMB) | Oct 28 | Registered direct | $4.5m | $1.50 | -1.3% | $1.65, to 2032 | A.G.P. | Not stated |

## The pattern

*Analysis: opinion, not investment advice*

Size bought better terms. Repligen, a supplier with [$209.3m of third-quarter revenue](https://www.sec.gov/Archives/edgar/data/730272/000162828026068562/rgen-20260930.htm), borrowed at a quarter of a per cent and set its conversion price above the market. Rapport did the same on its notes, but its stock sold at nearly a quarter below the last trade. Its [preliminary prospectus](https://www.sec.gov/Archives/edgar/data/2012593/000119312526434371/d348288d424b5.htm) already reported $436.1m at June 30th and cash into the second half of 2029. The raise moves that to the end of 2029, a modest extension bought with substantial dilution.

Rapport's insiders took part. A [Form 4](https://www.sec.gov/Archives/edgar/data/2012593/000110465926120789/tm2628672-1_4seq1.xml) shows that James Healy, a director, bought 952,380 shares at the $21.00 offering price through Sofinnova Venture Partners XI.

The two IPOs are a test of whether the window is open for companies that needed it. Both prospectuses flagged going-concern doubts before the money arrived, and both now claim cash into 2028.

Lower down, the discounts reflect cash, not bargaining. Actuate held $4.4m at June 30th, per its 10-Q, and the new shares are more than half of its post-deal count. It also agreed to give warrants to two holders managed by its directors Aaron Fletcher and Todd Thomson in return for a two-year lock-up. INmune's auditor included a going-concern paragraph in its 2025 report, and its UK filing for CORDStrom has slipped from July 2026 to February 2027. Aclaris priced on the day it reported Phase 1b data in which the eczema comparison rested on nine patients on drug and one on placebo. Equillium's investors bought at less than half the market price.

Nobody this week repeated Recursion's ATM-first pattern, which we [analysed](https://aibio.space/analysis/recursion-rxrx-dilution-atm-runway-2029/), though Vor's new ATM and INmune's right to use one after 60 days keep that route open. Nor did anyone match Absci's [no-discount sale](https://aibio.space/analysis/absci-absi-lilly-40m-stake-no-discount/), where Eli Lilly took $40m. Among deals with a prior close, only the debt issuers priced above the market.

## Disclosures

This is analysis and opinion about financings by several companies, not investment advice. aibio.space has no paid relationship with any company named in this piece. Deal terms come from SEC filings (prospectuses, 8-Ks, 10-Qs and Form 4s) and company press releases. Where a filing gives no prior close, we used Yahoo Finance price data and say so in the text. Figures marked as our own arithmetic are calculations from those sources.

## Sources

- [RGEN](https://aibio.space/companies/repligen/)
- [agreed on October 29th](https://www.sec.gov/Archives/edgar/data/730272/000162828026068382/rgen-20261029.htm)
- [release](https://www.sec.gov/Archives/edgar/data/730272/000162828026068382/rgen-20261030xexx992.htm)
- [third-quarter 10-Q](https://www.sec.gov/Archives/edgar/data/730272/000162828026068562/rgen-20260930.htm)
- [analysis](https://aibio.space/analysis/repligen-rgen-1b-convertible-notes-terms/)
- [RAPP](https://aibio.space/companies/rapport-therapeutics/)
- [priced](https://www.sec.gov/Archives/edgar/data/2012593/000119312526435030/d54357dfwp.htm)
- [pricing term sheet](https://www.sec.gov/Archives/edgar/data/2012593/000119312526435057/d59324dfwp.htm)
- [preliminary prospectus](https://www.sec.gov/Archives/edgar/data/2012593/000119312526434371/d348288d424b5.htm)
- [8-K](https://www.sec.gov/Archives/edgar/data/2012593/000119312526441851/d49801d8k.htm)
- [latest 10-Q](https://www.sec.gov/Archives/edgar/data/2012593/000119312526333862/rapp-20260630.htm)
- [sold](https://www.sec.gov/Archives/edgar/data/2044950/000162828026068563/0001628280-26-068563.txt)
- [sold](https://www.sec.gov/Archives/edgar/data/2124080/000119312526441782/0001193125-26-441782.txt)
- [ACRS](https://aibio.space/companies/aclaris-therapeutics/)
- [sold](https://www.sec.gov/Archives/edgar/data/1557746/000110465926119223/tm2627632-2_424b5.htm)
- [latest 10-Q](https://www.sec.gov/Archives/edgar/data/1557746/000110465926092065/acrs-20260630x10q.htm)
- [Our coverage](https://aibio.space/news/aclaris-therapeutics-prices-49-999-934-stock-pre-funded-warrant/)
- [EQ](https://aibio.space/companies/equillium/)
- [triggered](https://www.sec.gov/Archives/edgar/data/1746466/000119312526432158/d67574dex991.htm)
- [latest 10-Q](https://www.sec.gov/Archives/edgar/data/1746466/000119312526349235/eq-20260630.htm)
- [Our coverage](https://aibio.space/news/first-eq504-dosing-unlocks-20-million-private-placement-tranche/)
- [ACTU](https://aibio.space/companies/actuate-therapeutics/)
- [sold](https://www.sec.gov/Archives/edgar/data/1652935/000168316826008122/actuate_424b5.htm)
- [latest 10-Q](https://www.sec.gov/Archives/edgar/data/1652935/000168316826006472/actuate_i10q-063026.htm)
- [Our coverage](https://aibio.space/news/actuate-therapeutics-prices-11-0-million-offering-shares-warrants/)
- [INMB](https://aibio.space/companies/inmune-bio/)
- [bought](https://www.sec.gov/Archives/edgar/data/1711754/000121390026113531/ea0308597-424b5_inmune.htm)
- [latest 10-Q](https://www.sec.gov/Archives/edgar/data/1711754/000121390026086135/ea0298894-10q_inmune.htm)
- [Our coverage](https://aibio.space/news/inmune-bio-raises-4-50-million-registered-direct-offering-warrants/)
- [ALT](https://aibio.space/companies/altimmune/)
- [drew $10.0m](https://www.sec.gov/Archives/edgar/data/1326190/000132619026000060/alt-20261027x8k.htm)
- [VBIO](https://aibio.space/companies/valion-bio/)
- [receives](https://www.sec.gov/Archives/edgar/data/1787740/000143774926033552/vbio20261023_8k.htm)
- [at-the-market prospectus](https://www.sec.gov/Archives/edgar/data/1817229/000119312526439975/0001193125-26-439975.txt)
- [Form 4](https://www.sec.gov/Archives/edgar/data/2012593/000110465926120789/tm2628672-1_4seq1.xml)
- [analysed](https://aibio.space/analysis/recursion-rxrx-dilution-atm-runway-2029/)
- [no-discount sale](https://aibio.space/analysis/absci-absi-lilly-40m-stake-no-discount/)

Every figure comes from the documents above. Chart values come from the company's financial statements as tagged in its SEC filings; derived values are labelled. If you find an error, [tell us](https://aibio.space/reputation/#update).

## Investor Chat

Loading posts…

---
Source page: https://aibio.space/analysis/biotech-financing-roundup-week-2026-11-01/. Facts in aibio.space stories are checked against company filings and releases; opinion is labelled. Cite as: aibio.space, "Biotech financings Oct 26 to Nov 1: Repligen, Rapport lead", 2026-11-01, https://aibio.space/analysis/biotech-financing-roundup-week-2026-11-01/
